Style | Citing Format |
---|---|
MLA | Ashtari F, et al.. "Assessment of Intelligence Quotient in Patients With Neuromyelitis Optica Spectrum Disease and Multiple Sclerosis." Multiple Sclerosis and Related Disorders, vol. 70, no. , 2023, pp. -. |
APA | Ashtari F, Manouchehri N, Shaygannejad V, Barekatain M, Adibi I, Afsharisafavi A, Ramezani N, Ghalamkari A, Barzegar M (2023). Assessment of Intelligence Quotient in Patients With Neuromyelitis Optica Spectrum Disease and Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 70(), -. |
Chicago | Ashtari F, Manouchehri N, Shaygannejad V, Barekatain M, Adibi I, Afsharisafavi A, Ramezani N, Ghalamkari A, Barzegar M. "Assessment of Intelligence Quotient in Patients With Neuromyelitis Optica Spectrum Disease and Multiple Sclerosis." Multiple Sclerosis and Related Disorders 70, no. (2023): -. |
Harvard | Ashtari F et al. (2023) 'Assessment of Intelligence Quotient in Patients With Neuromyelitis Optica Spectrum Disease and Multiple Sclerosis', Multiple Sclerosis and Related Disorders, 70(), pp. -. |
Vancouver | Ashtari F, Manouchehri N, Shaygannejad V, Barekatain M, Adibi I, Afsharisafavi A, et al.. Assessment of Intelligence Quotient in Patients With Neuromyelitis Optica Spectrum Disease and Multiple Sclerosis. Multiple Sclerosis and Related Disorders. 2023;70():-. |
BibTex | @article{ author = {Ashtari F and Manouchehri N and Shaygannejad V and Barekatain M and Adibi I and Afsharisafavi A and Ramezani N and Ghalamkari A and Barzegar M}, title = {Assessment of Intelligence Quotient in Patients With Neuromyelitis Optica Spectrum Disease and Multiple Sclerosis}, journal = {Multiple Sclerosis and Related Disorders}, volume = {70}, number = {}, pages = {-}, year = {2023} } |
RIS | TY - JOUR AU - Ashtari F AU - Manouchehri N AU - Shaygannejad V AU - Barekatain M AU - Adibi I AU - Afsharisafavi A AU - Ramezani N AU - Ghalamkari A AU - Barzegar M TI - Assessment of Intelligence Quotient in Patients With Neuromyelitis Optica Spectrum Disease and Multiple Sclerosis JO - Multiple Sclerosis and Related Disorders VL - 70 IS - SP - EP - PY - 2023 ER - |